Trial
NCT03429101
A Study of Poziotinib in Combination With T-DM1 in HER2-Positive Breast Cancer
Phase ITERMINATEDSAFETYConfidence: MEDIUM
Sponsor
Spectrum Pharmaceuticals, Inc
Collaborators
—
Condition
Breast Cancer
Intervention
Poziotinib
Why stopped
Dose limiting toxicity
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2021-01-15